JP2010518091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518091A5 JP2010518091A5 JP2009549130A JP2009549130A JP2010518091A5 JP 2010518091 A5 JP2010518091 A5 JP 2010518091A5 JP 2009549130 A JP2009549130 A JP 2009549130A JP 2009549130 A JP2009549130 A JP 2009549130A JP 2010518091 A5 JP2010518091 A5 JP 2010518091A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- bryologs
- pharmaceutical
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003923 Protein Kinase C Human genes 0.000 claims description 7
- 108090000315 Protein Kinase C Proteins 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 6
- 150000001982 diacylglycerols Chemical class 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical class C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- MJMJERJFCHYXEM-UHFFFAOYSA-N 5-chloro-N-heptyl-1-naphthalenesulfonamide Chemical group C1=CC=C2C(S(=O)(=O)NCCCCCCC)=CC=CC2=C1Cl MJMJERJFCHYXEM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- -1 bicyclic triterpenoids Chemical class 0.000 claims 5
- 206010019196 Head injury Diseases 0.000 claims 3
- 150000004141 diterpene derivatives Chemical class 0.000 claims 3
- ZFIFHAKCBWOSRN-UHFFFAOYSA-N naphthalene-1-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1 ZFIFHAKCBWOSRN-UHFFFAOYSA-N 0.000 claims 3
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 claims 2
- 229940123948 Diacylglycerol kinase inhibitor Drugs 0.000 claims 2
- CGPFADLKIPZYRE-OWLUANBVSA-N daphnane Chemical compound C([C@]12CCC[C@H]1[C@]13CCC)C[C@H]4[C@]3(C)CC[C@H](C(C)C)[C@@H]1N2C4 CGPFADLKIPZYRE-OWLUANBVSA-N 0.000 claims 2
- 239000003047 diacylglycerol kinase inhibitor Substances 0.000 claims 2
- 229930004069 diterpene Natural products 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- RVAQSYWDOSHWGP-UHFFFAOYSA-N 1-[ethoxy(trichloromethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(C(Cl)(Cl)Cl)OCC RVAQSYWDOSHWGP-UHFFFAOYSA-N 0.000 claims 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 claims 1
- GIMKEHNOTHXONN-QBZCICILSA-N Ingenol 3,20-dibenzoate Natural products O=C(OCC=1[C@@H](O)[C@]2(O)[C@@H](OC(=O)c3ccccc3)C(C)=C[C@@]32[C@@H](C)C[C@H]2C(C)(C)[C@@H]2[C@H](C3=O)C=1)c1ccccc1 GIMKEHNOTHXONN-QBZCICILSA-N 0.000 claims 1
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims 1
- GIMKEHNOTHXONN-UHFFFAOYSA-N Ingenol-3,20-dibenzoate Natural products OC1C2(O)C(OC(=O)C=3C=CC=CC=3)C(C)=CC2(C2=O)C(C)CC(C3(C)C)C3C2C=C1COC(=O)C1=CC=CC=C1 GIMKEHNOTHXONN-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- UEZROEGYRDHMRV-UHFFFAOYSA-N [1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound O=C1C=CN=C2SC=CN12 UEZROEGYRDHMRV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 1
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 claims 1
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims 1
- 229960002993 ingenol mebutate Drugs 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 150000004633 phorbol derivatives Chemical class 0.000 claims 1
- 239000002644 phorbol ester Substances 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- CONYTTFKIUJZOF-UHFFFAOYSA-N 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoic acid Chemical compound CCCCCC1CC1CC1C(CCCCCCCC(O)=O)C1 CONYTTFKIUJZOF-UHFFFAOYSA-N 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90033807P | 2007-02-09 | 2007-02-09 | |
| US60/900,338 | 2007-02-09 | ||
| US92466307P | 2007-05-24 | 2007-05-24 | |
| US60/924,663 | 2007-05-24 | ||
| PCT/US2008/001755 WO2008100449A2 (en) | 2007-02-09 | 2008-02-11 | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013261788A Division JP6199176B2 (ja) | 2007-02-09 | 2013-12-18 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518091A JP2010518091A (ja) | 2010-05-27 |
| JP2010518091A5 true JP2010518091A5 (enExample) | 2011-07-28 |
| JP5518489B2 JP5518489B2 (ja) | 2014-06-11 |
Family
ID=39690678
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549130A Active JP5518489B2 (ja) | 2007-02-09 | 2008-02-11 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
| JP2013261788A Expired - Fee Related JP6199176B2 (ja) | 2007-02-09 | 2013-12-18 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
| JP2016016127A Pending JP2016128486A (ja) | 2007-02-09 | 2016-01-29 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013261788A Expired - Fee Related JP6199176B2 (ja) | 2007-02-09 | 2013-12-18 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
| JP2016016127A Pending JP2016128486A (ja) | 2007-02-09 | 2016-01-29 | 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9974832B2 (enExample) |
| EP (4) | EP2121000B1 (enExample) |
| JP (3) | JP5518489B2 (enExample) |
| KR (2) | KR20090119894A (enExample) |
| CN (1) | CN101848726A (enExample) |
| CA (2) | CA2674773A1 (enExample) |
| ES (1) | ES2548766T3 (enExample) |
| WO (1) | WO2008100449A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2305234T3 (es) | 2001-02-27 | 2008-11-01 | Blanchette Rockefeller Neurosciences Institute | Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno. |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| WO2007016202A1 (en) | 2005-07-29 | 2007-02-08 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| KR20090120480A (ko) * | 2007-02-09 | 2009-11-24 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 허혈/뇌졸중-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련된 물질의 치료학적 효과 |
| WO2008100449A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| WO2008143880A2 (en) * | 2007-05-24 | 2008-11-27 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury |
| US20100168219A1 (en) * | 2008-12-31 | 2010-07-01 | Jonathan Steven Alexander | Chronic inflammation and transplantation |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| WO2010014588A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
| CA2941035A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| US20110054040A1 (en) * | 2008-12-22 | 2011-03-03 | Department Of Biotechnology | Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy |
| US20110212474A1 (en) | 2009-10-02 | 2011-09-01 | Blanchette Rockefeller Neurosciences Institute | Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells |
| JP6058395B2 (ja) | 2009-10-02 | 2017-01-11 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | アルツハイマー病の診断のための繊維芽細胞成長パターン |
| WO2012006516A2 (en) | 2010-07-08 | 2012-01-12 | Alkon Daniel L | Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke |
| KR101467605B1 (ko) * | 2010-11-29 | 2014-12-04 | 충북대학교 산학협력단 | 신규의 다프난 디테르펜계 화합물 및 이를 유효성분으로 포함하는 피부 미백용 조성물 |
| JP6563193B2 (ja) | 2011-11-13 | 2019-08-21 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｄｃｐｌａのエステル、およびそれを用いた処置の方法 |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| US10828276B2 (en) | 2012-11-28 | 2020-11-10 | Aphios Corporation | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
| WO2014145316A1 (en) | 2013-03-15 | 2014-09-18 | Alkon Daniel L | Methods for identifying neuroprotective pkc activators |
| WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
| WO2019222564A1 (en) * | 2018-05-18 | 2019-11-21 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| EP0115472A3 (de) | 1983-01-27 | 1985-10-02 | Ciba-Geigy Ag | Pyrrolidinonderivate und Verfahren zu ihrer Herstellung |
| US4611066A (en) | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5962498A (en) | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
| US5891906A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
| US6043270A (en) | 1986-06-11 | 2000-03-28 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators V |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5955501A (en) | 1986-06-11 | 1999-09-21 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators O |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| ATE97321T1 (de) | 1988-01-13 | 1993-12-15 | Univ Arizona State | Immunmodulierende bryostatine. |
| US4833139A (en) * | 1988-01-25 | 1989-05-23 | Hoechst-Roussel Pharmaceuticals, Inc. | Enhancing cholinergic activity with 5-substituted 1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinones and related compounds |
| DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| US4994472A (en) | 1989-08-02 | 1991-02-19 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-(pyridinylamino)-2-pyrrolidinones as pain relievers |
| EP0502060A4 (en) | 1989-11-13 | 1993-05-05 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| JP2578001B2 (ja) | 1989-12-11 | 1997-02-05 | 明治製菓株式会社 | 抗痴呆薬 |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| US5072004A (en) | 1990-12-31 | 1991-12-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthetic conversion of bryostatin 2 into bryostatin 1 |
| US5981165A (en) | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
| US5196447A (en) | 1991-08-08 | 1993-03-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University | Neristatin 1 |
| AU675054B2 (en) | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US5359115A (en) | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| CA2143848C (en) | 1992-10-01 | 2007-09-11 | W. Clark Still | Complex combinatorial chemical libraries encoded with tags |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| US5580748A (en) * | 1993-05-03 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic tests for alzheimers disease |
| US5976816A (en) * | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US5393897A (en) | 1993-07-02 | 1995-02-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of spongistatins 5,7,8 and 9 |
| US5362899A (en) | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| ATE176906T1 (de) | 1993-09-30 | 1999-03-15 | Shionogi & Co | Benzolactam-derivate |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5430053A (en) * | 1994-04-19 | 1995-07-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of dictyostatin 1 |
| US5625232A (en) * | 1994-07-15 | 1997-04-29 | Texas Instruments Incorporated | Reliability of metal leads in high speed LSI semiconductors using dummy vias |
| EP0854874B1 (en) * | 1994-11-10 | 2003-05-02 | Pfizer Inc. | Macrocyclic lactone compounds and their production process |
| GB9509572D0 (en) | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
| CA2253463A1 (en) | 1996-05-10 | 1997-11-20 | Georgetown University | 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and their use as protein kinase c (=pkc) modulators |
| GB9620390D0 (en) * | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB9701675D0 (en) | 1997-01-28 | 1997-03-19 | Bridgeman Keith | Composition for the treatment of parkinson's disease |
| PL339219A1 (en) | 1997-09-08 | 2000-12-04 | Univ Georgetown | Substituted 2-pyrolydinones as pkc activators |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| DE19943198A1 (de) | 1999-09-09 | 2001-03-15 | Meyer Lucas Gmbh & Co | Therapeutikum zur Behebung zentralnervöser Funktionsstörungen |
| JP2003515601A (ja) * | 1999-11-30 | 2003-05-07 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | ブリオスタチンアナログ、合成方法および使用 |
| JP2001240581A (ja) | 2000-02-29 | 2001-09-04 | Senju Pharmaceut Co Ltd | アミノベンズアミド誘導体およびその用途 |
| AU2001243635A1 (en) * | 2000-03-14 | 2001-09-24 | Brown University Research Foundation | Methods and compositions for regulating memory consolidation |
| US20040019018A1 (en) | 2000-04-28 | 2004-01-29 | Lixin Qlao | Rigid pyrrolidone modulators of pkc |
| AUPQ801700A0 (en) | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| US20030050302A1 (en) * | 2000-08-31 | 2003-03-13 | Neurologic, Inc. | Treatment of conditions associated with amyloid processing using PKC activators |
| DK1195159T3 (da) | 2000-10-09 | 2006-10-02 | Matthias Dr Med Rath | Terapeutisk kombination af ascorbat med lysin og arginin til forebyggelse eller behandling af cancer |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| AUPR215700A0 (en) | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| EP1363606A1 (en) | 2001-03-01 | 2003-11-26 | Pfizer Products Inc. | Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders |
| WO2002083877A1 (en) | 2001-04-11 | 2002-10-24 | Stem Cell Therapeutics Inc. | Production of tyrosine hydroxylase positive neurons |
| US20040247571A1 (en) | 2001-04-23 | 2004-12-09 | Xia Meijer | Neural cells expressing tyrosine hydroxylase |
| CA2446074C (en) | 2001-05-02 | 2011-09-06 | Blanchette Rockefeller Neurosciences Institute | Carbonic anhydrase activators for enhancing learning and memory |
| CA2401452A1 (en) | 2001-09-04 | 2003-03-04 | Uri Saragovi | Combination of antioxidant substances for the treatment of alzheimer's disease |
| JP4568464B2 (ja) | 2001-11-07 | 2010-10-27 | 雪印乳業株式会社 | 記憶障害予防治療剤 |
| WO2004004641A2 (en) * | 2002-07-02 | 2004-01-15 | Blanchette Rockefeller Neurosciences Institute | PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| US6821979B2 (en) | 2002-03-07 | 2004-11-23 | Blanchette Rockefeller Neurosciences Institute | Synergistic enhancement of cognitive ability |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) * | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20040229292A1 (en) * | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
| US7803400B2 (en) * | 2002-12-03 | 2010-09-28 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| NZ546226A (en) | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| EP1761805B1 (en) | 2004-06-30 | 2013-05-01 | Shell Internationale Research Maatschappij B.V. | Determining in-situ the relation between seismic velocity and state of stress in an underground formation |
| WO2007016202A1 (en) | 2005-07-29 | 2007-02-08 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| JP2009544753A (ja) * | 2006-07-28 | 2009-12-17 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法 |
| WO2008100449A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| JP5987867B2 (ja) | 2014-07-10 | 2016-09-07 | コニカミノルタ株式会社 | シート搬送装置および画像形成システム |
-
2008
- 2008-02-11 WO PCT/US2008/001755 patent/WO2008100449A2/en not_active Ceased
- 2008-02-11 ES ES08725395.1T patent/ES2548766T3/es active Active
- 2008-02-11 CA CA002674773A patent/CA2674773A1/en not_active Withdrawn
- 2008-02-11 CA CA2873179A patent/CA2873179A1/en not_active Abandoned
- 2008-02-11 KR KR1020097018890A patent/KR20090119894A/ko not_active Ceased
- 2008-02-11 EP EP08725395.1A patent/EP2121000B1/en not_active Not-in-force
- 2008-02-11 KR KR1020147006408A patent/KR20140049054A/ko not_active Ceased
- 2008-02-11 EP EP14001303.8A patent/EP2754448A3/en not_active Withdrawn
- 2008-02-11 EP EP18153508.9A patent/EP3332797A3/en not_active Withdrawn
- 2008-02-11 US US12/068,742 patent/US9974832B2/en active Active
- 2008-02-11 JP JP2009549130A patent/JP5518489B2/ja active Active
- 2008-02-11 CN CN200880004009A patent/CN101848726A/zh active Pending
- 2008-02-11 EP EP15002036.0A patent/EP2959914A1/en not_active Ceased
-
2013
- 2013-12-18 JP JP2013261788A patent/JP6199176B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-29 JP JP2016016127A patent/JP2016128486A/ja active Pending
-
2018
- 2018-04-17 US US15/954,693 patent/US20190083575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518091A5 (enExample) | ||
| JP6475727B2 (ja) | 新規方法 | |
| WO2008100449A4 (en) | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury | |
| EE05450B1 (et) | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine | |
| JP2012509846A5 (enExample) | ||
| PE20100156A1 (es) | Tratamiento de nafld | |
| JP2009114205A (ja) | 心臓血管系および中枢神経系の特定疾病を治療するための縮合（ヘタリール置換）１−ベンジル−３−ピラゾール誘導体の使用 | |
| EA200000700A3 (ru) | НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ | |
| AR062792A1 (es) | Derivados azetidinona y metodos de uso de estos | |
| JP2007515400A5 (enExample) | ||
| TNSN08408A1 (fr) | PYRIDINE [3,4-b] PYRAZINONES | |
| JP2012505836A5 (enExample) | ||
| WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
| AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
| JP2006514611A5 (enExample) | ||
| EP2075250A3 (en) | Thrombin receptor antagonists | |
| DE602005005165D1 (de) | Verfahren zur verbesserung der bioverfügbarkeit von ospemifen | |
| JP2001031566A (ja) | ペットの問題行動抑制組成物 | |
| JP2002537284A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| JP2012505905A5 (enExample) | ||
| JP2014504648A5 (enExample) | ||
| AU2010297405B2 (en) | Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases | |
| BRPI0011404B8 (pt) | microgrânulos de sulfato de morfina de liberação prolongada, processo de preparação dos mesmos e composição farmacêutica. | |
| JP2008526953A (ja) | 炎症性疾患のプラジカンテルでの治療 |